{
    "clinical_study": {
        "@rank": "3223", 
        "acronym": "CIRCE", 
        "arm_group": [
            {
                "arm_group_label": "Chemo-induction", 
                "arm_group_type": "Experimental", 
                "description": "Cisplatin plus Gemcitabine for 3 cycles followed by Cisplatin, radiotherapy and brachytherapy"
            }, 
            {
                "arm_group_label": "Chemoradiotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Cisplatin, radiotherapy and brachytherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this phase II study is to determine the survival free disease of patients\n      diagnosed with invasive locally advanced carcinomas of uterine cervix treated with induction\n      chemotherapy with cisplatin and gemcitabine followed by chemoradiation and definitive\n      chemoradiation."
        }, 
        "brief_title": "Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.", 
        "condition": "Patients Diagnosed With Advanced Carcinoma of Uterine Cervix t", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Uterine Cervical Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Advanced carcinoma of uterine cervix histological confirmed.\n\n          2. Indication for definitive chemoradiation treatment;\n\n          3. Measurable disease by RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)\n             criteria;\n\n          4. Age between 18 years old and 70 years old;\n\n          5. Adequate bone marrow and organ function defined by laboratory values;\n\n          6. Non evidence of disease in para-aortic lymph node;\n\n        Exclusion Criteria:\n\n          1. Previous treatment with Chemotherapy or radiotherapy\n\n          2. Previous surgery for primary tumor;\n\n          3. Distant metastasis;\n\n          4. Performance status according to Eastern Cooperative Oncology Group greater than 2;\n\n          5. Peripheric neuropathy greater than grade 2 by National Cancer Institute Common\n             Toxicity Criteria for Adverse Events (NCI-CTCAE) version 3.0;\n\n          6. Significant Cardiac disease (history of and/or active disease);\n\n          7. Other treatment for cancer, including hormonotherapy;\n\n          8. Psychiatric or addictive disorders or other conditions that, in the opinion of the\n             investigator, would preclude the patient from meeting the study requirements;"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973101", 
            "org_study_id": "NP 217/2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chemo-induction", 
                "description": "50 mg/m2 - Day 1", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Chemo-induction", 
                "description": "Gemcitabine 1000mg/m2 on day 1 and day 8.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Chemo-induction", 
                    "Chemoradiotherapy"
                ], 
                "description": "Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.", 
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Chemo-induction", 
                    "Chemoradiotherapy"
                ], 
                "description": "45 Gy", 
                "intervention_name": "Radiotherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": [
                    "Chemo-induction", 
                    "Chemoradiotherapy"
                ], 
                "description": "80 Gy", 
                "intervention_name": "Brachytherapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Advanced carcinomas of uterine cervix", 
            "Chemoradiation", 
            "Chemo-induction", 
            "Cisplatin", 
            "Gemcitabine"
        ], 
        "lastchanged_date": "October 25, 2013", 
        "location": {
            "contact": {
                "email": "pesquisa.clinica@icesp.org.br", 
                "last_name": "Maria Del Pilar Estevez Diz, MD", 
                "phone": "55 11 3893-2000"
            }, 
            "facility": {
                "address": {
                    "city": "S\u00e3o Paulo", 
                    "country": "Brazil", 
                    "state": "SP"
                }, 
                "name": "ICESP"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II, Prospective, Randomized, Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.", 
        "overall_contact": {
            "email": "pesquisa.clinica@icesp.org.br", 
            "last_name": "Maria Del Pilar Estevez Diz, MD", 
            "phone": "55 11 3893-2000"
        }, 
        "overall_official": {
            "affiliation": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
            "last_name": "Maria Del Pilar Estevez Diz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease free survival", 
            "safety_issue": "Yes", 
            "time_frame": "From the randomization until the end of the treatment - up to 36 month."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973101"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rate", 
                "safety_issue": "Yes", 
                "time_frame": "36 month after the end of the treatment."
            }, 
            {
                "measure": "Locoregional disease control rate", 
                "safety_issue": "Yes", 
                "time_frame": "36 month after the end of treatment."
            }, 
            {
                "measure": "Acute and chronic toxicity in both arms", 
                "safety_issue": "Yes", 
                "time_frame": "From the randomization until the end of the treatment."
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "36 month after the end of the treatment."
            }
        ], 
        "source": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}